ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC by Dr. Edward Garon

Article

Responses in the CNSDr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

 

[powerpress]

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC by Dr. Edward Garon

Article

ERCC1 and PlatinumDr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of predictive biomarkers ERCC1 and RRM1 in advanced NSCLC.

 

[powerpress]

Case Discussion on Adjuvant Therapy for Stage IB NSCLC with Dr. Nasser Hanna

Article

It's been a few months since I sat down with my friend, Dr. Nasser Hanna, a great lung cancer expert from Indiana University, and also a friend in the field. Those of you who have been following GRACE content for a while may have come across his name: he's led a few of the more important trials that are part of our current core knowledge in lung cancer now, such as the

Dr. Pennell on Emerging Molecular Markers in NSCLC Management: Podcast Now Available

Article

We know that many people interested in the topics we discuss in our webinars may not be able to attend the live programs, but we're committed to offering our content to people as easily as possible. Accordingly, here is the podcast version of Dr. Pennell's very well received presentation on a range of molecular markers currently being used and others emerging in clinical trials as potential tools for the coming years.

Below you'll find the audio versions of the presentation.

 

What I really do: Molecular testing for NSCLC

Article

I'm fortunate to practice at Moffitt, where Dr. Gerold Bepler and Dr. George Simon pioneered a molecularly directed approach to front-line chemotherapy in NSCLC. Data from the phase II clinical trial demonstrated impressive median survival for a platinum-based doublet: 13.3 months. The schema of the MADeIT clinical trial is shown below and I'm happy to say that I am able to put many of my patients on this clinical trial. Dr.

Molecular markers for chemotherapy—are we there yet?

Article

Are we theeeeere yet?” Every parent knows that familiar whining from the back seat of the car. Sometimes, I feel as impatient as the kid in the back of the car. Although EGFR mutation helps with predicting tarceva (erlotinib) response, I want markers for cytotoxic (traditional) chemotherapy now. Unlike the parent in the driver’s seat of the car, I’m not entirely sure where we are, or where we’re going. Sometimes I feel as though I’m driving in the dark. Could molecular markers be the headlights?